Literature DB >> 30273544

Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.

Mo Cheng1, Weiluo Cai1, Wending Huang1, Yong Chen1, Zhiqiang Wu1, Peng Luo1, Wangjun Yan2.   

Abstract

Emerging evidence shows that cytokines such as interleukins (ILs) are involved in the progression and chemoresistance of multiple tumors, including osteosarcoma (OS). Our present study established the doxorubicin (Dox) resistant human OS MG-63 and HOS cells and named them MG-63/Dox and HOS/Dox, respectively. The expression of IL-8, while not VEGFA, IL-32, or IL-34, was significantly increased in OS/Dox cells as compared with that in the parental cells. IL-8 neutralization antibody can significantly increase the Dox sensitivity of OS/Dox cells. Further, IL-8 can up regulate ABCB1, which encodes one important ATP-binding cassette (ABC) transporter /P-glycoprotein (P-gp). Mechanically, IL-8 increased the transcription of ABCB1 via up regulating its promoter activity, while had no effect on its protein or mRNA stability. Targeted inhibition of p65 can attenuate IL-8 induced transcription of ABCB1 in OS cells. Treatment OS cells with 5-aza-dC, the inhibitor of DNMT, had no effect on expression of IL-8. Expression of HDAC6 in MG-63/Dox and HOS/Dox cells was significantly greater than that in their parental cells. Knockdown of HDAC6 can suppress the expression of IL-8 in OS cells. Collectively, our data showed that HDAC6 mediated upregulation of IL-8 can regulate the Dox sensitivity of OS cells via transcriptionally regulating the expression of ABCB1. Targeted inhibition of IL-8 might be a potent potential approach for overcome the Dox resistance of OS cells and helpful for clinical therapy of OS patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ABCB1; Doxorubicin; HDAC6; IL-8; Osteosarcoma

Mesh:

Substances:

Year:  2018        PMID: 30273544     DOI: 10.1016/j.ejphar.2018.09.032

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers.

Authors:  Kuo Chen; Jin Zhang; Narasimha M Beeraka; Chengyun Tang; Yulia V Babayeva; Mikhail Y Sinelnikov; Xinliang Zhang; Jiacheng Zhang; Junqi Liu; Igor V Reshetov; Olga A Sukocheva; Pengwei Lu; Ruitai Fan
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

Review 2.  Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.

Authors:  Kristen Fousek; Lucas A Horn; Claudia Palena
Journal:  Pharmacol Ther       Date:  2020-09-24       Impact factor: 12.310

3.  Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.

Authors:  Shen-Jun Yuan; Yong-Hong Xu; Chao Wang; Hui-Chao An; Hua-Zhen Xu; Ke Li; Naoki Komatsu; Li Zhao; Xiao Chen
Journal:  J Nanobiotechnology       Date:  2019-10-17       Impact factor: 10.435

4.  Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.

Authors:  Chung-Pu Wu; Cheng-Yu Hung; Sabrina Lusvarghi; Yen-Fu Chang; Sung-Han Hsiao; Yang-Hui Huang; Tai-Ho Hung; Jau-Song Yu; Suresh V Ambudkar
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.